Moderna (NASDAQ:MRNA) shares rose 2.9% in pre-market trading, recovering some ground after several sessions of declines that followed a dramatic rally triggered by positive Phase 3 results for its personalised mRNA cancer vaccine, intismeran autogene.
Moderna and partner Merck recently announced that intismeran met the primary endpoint in a late-stage Phase 3 trial, demonstrating a meaningful reduction in melanoma recurrence among patients whose tumours had previously been surgically removed. The result marked the first successful late-stage trial outcome for an mRNA-based cancer vaccine and prompted a sharp revaluation of Moderna shares.
Recent profit-taking has since cooled the rally, with investors reassessing the potential commercial opportunity and risks surrounding the treatment following the initial enthusiasm.
Barclays Raises Moderna Price Target to $125
Fresh analyst commentary provided additional support for Moderna shares ahead of Tuesday’s opening bell.
Barclays analyst Eliana Merle increased the firm’s price target on Moderna to $125 from $48 while maintaining an Equal Weight rating on the stock. The substantial target increase followed the encouraging Phase 3 intismeran results.
Wolfe Research had previously upgraded Moderna from Underperform to Peerperform following the trial data. Its analysts estimated potential unadjusted peak sales of $9.2 billion across four indications: adjuvant melanoma, renal cell carcinoma (RCC), muscle-invasive bladder cancer (MIBC) and non-small cell lung cancer (NSCLC), before accounting for Moderna’s profit-sharing arrangement with Merck.
Despite the more favourable analyst assessments, investors continue to evaluate the commercial prospects for intismeran and whether the vaccine can ultimately translate its clinical success into substantial revenue.
Moderna Remains Volatile After 392% Year-to-Date Rally
The latest rebound follows an extraordinary period for Moderna shares, which have gained approximately 392% year to date following the successful Phase III melanoma trial.
That surge has been accompanied by considerable volatility. The initial response to the trial results drove the shares sharply higher before profit-taking and weakness across parts of the biotechnology sector triggered a subsequent correction.
Merck, Moderna’s development partner for intismeran, has also benefited from optimism surrounding the programme, while investors across the biotechnology industry have been reassessing the implications of the first positive Phase 3 result for an mRNA cancer vaccine.
Broader Market Gains Support Moderna Recovery
Conditions across U.S. equities were also favourable for Tuesday’s rebound. The Nasdaq Composite advanced 1.0%, while the S&P 500 gained 0.5%, providing a supportive environment for higher-risk biotechnology stocks.
The combination of stronger broader markets, the substantial Barclays price-target increase and stabilisation following Moderna’s recent correction helped lift the shares in pre-market trading.
Attention is now turning towards the potential commercial pathway for intismeran. Analysts have identified 2027 as a possible commercialisation year for mRNA cancer vaccines if the programme continues to deliver supportive data and clears the necessary regulatory hurdles.
That longer-term opportunity continues to underpin interest in Moderna (NASDAQ:MRNA), although the shares remain below their 52-week high of $176.66 following their recent period of exceptional volatility.